Navigation Links
XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
Date:12/12/2012

AUSTIN, Texas, Dec. 12, 2012 /PRNewswire/ -- XBiotech Inc., a privately held biotechnology company, today announced positive Phase II clinical trial results in the treatment of acne vulgaris.  The trial was conducted as an open label study using XBiotech's lead candidate, True Human™ monoclonal antibody MABp1, in patients with moderate to severe disease.  Patients enrolled in the study demonstrated continual improvement in lesions over the course of therapy, with up to 42 percent reduction in eight weeks. The excellent safety profile of MABp1 demonstrated across multiple therapeutic indications to date, and strong initial results in this trial, provide the basis for further development of the first biologic therapy targeting the inflammatory cytokine IL-1α for acne treatment.

(Logo: http://photos.prnewswire.com/prnh/20121017/MM95359LOGO)

Acne vulgaris is a common skin disease that affects an estimated 80% of Americans at some time during their lives. Twenty percent will have severe acne, which results in permanent physical and mental scarring. Acne vulgaris is America's most common skin disease and is characterized by non-inflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules.

Currently, there are several approved topical and systemic treatments however no biological therapy has yet been approved for the treatment of acne.  The Phase II clinical trial involving the XBiotech proprietary platform technology was a multicenter study, and included leading investigators such as Dr. Ronald Moy, recent President of the American Academy of Dermatology, former Co-Chief of Dermatology, and Chief of Dermatological Surgery at UCLA Medical Center.  

"We believe that our True Human™ monoclonal antibody therapy has the potential to provide a completely new biologic approach to the management of acne," said John Simard, president and CEO of XBiotech.  "The safety of our technology – which has been well established with 145 patients receiving over 450 doses of MABp1 – allows us to focus on a variety of indications, including those that are non-life threatening such as acne. As with other conditions involving chronic inflammation, IL-1α plays a significant role in the acne disease process and neutralizing its effects with MABp1 shows highly promising early results. The opportunity to address a common, yet challenging, skin condition with a novel biological drug represents a significant development in dermatological care."

About True Human™ Antibodies

True Human™ antibodies represent the next generation of therapeutic antibodies.  These antibodies are identified using the Company's proprietary platform technology to ensure faithful reproduction of the original human antibody gene.  True Human antibodies are "invisible" to the body's immune system and thus have the potential for better safety, efficacy and patient tolerability compared to earlier generation antibody therapeutics.

About XBiotech

XBiotech is pioneering breakthrough therapies that improve the safety and efficacy of antibody therapeutics. The Company's lead product candidate inhibits chronic sterile inflammation by targeting IL-1α, a master regulator of inflammation. The clinical development program addresses tremendous unmet medical need in multiple disease indications including, acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease. XBiotech is also revolutionizing scalable, flexible manufacturing systems for the production of biological therapies.  Using minimal infrastructure and disposable bioreactor technology – to dramatically reduce capital requirements, operating complexity, and lead times - the Company has established a compelling commercialization path for its True Human™ antibody platform.  For more information on how XBiotech is advancing human monoclonal antibody therapy please visit www.xbiotech.com.

Contact: 
Investors: 
John Simard
XBiotech
info@xbiotech.com
512.386.2930

Media:
Aaron DeLucia
Porter Novelli
aaron.delucia@porternovelli.com
512.241.2249


'/>"/>
SOURCE XBiotech Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
2. Career Confidential Announces Release of New E-book About Using Recruiters
3. Pittcon Announces 2013 Award Recipients; New Award, Robert Boyle Prize for Analytical Science, Added to Technical Program
4. Innosight Announces Leadership Transition
5. My Cleaning Products Announces its Christmas Special, Sells Rusterizer at 20% Less
6. GenScript Announces Collaboration with AMDeC: Seeks to Decrease Biological Research Costs at NYC Area Institutions
7. Sequenom Announces Leadership Appointments
8. Rusty Cage Announces Rusterizer's 30% New Year Special Discount
9. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
10. Verenium Announces $22.5 Million, Five-Year Secured Financing
11. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 22, 2017 , ... ... leaders in designating infertility as a disease, bringing new hope for prospective parents ... their 2017 annual meeting to back the World Health Organization’s designation in hopes ...
(Date:6/22/2017)... ... ... The first human cell line HeLa, established in 1951, has entered cell ... human cell lines with HeLa cells were published. Until recently, cross-contamination and misidentification of ... associated with dramatic consequences for research. , In this educational webinar, which is ...
(Date:6/20/2017)... CT (PRWEB) , ... June 20, 2017 , ... ... today announced that the CTNext board of directors has formed a Higher Education ... a working group composed of institution presidents and other high-ranking representatives from 35 ...
(Date:6/20/2017)...  Kibow Biotech Inc., a pioneer in developing "Enteric ... a new patent covering a unique method for preventing ... and Trademark Office on May 23 rd 2017. ... Bio award in 2014 in San Diego, ... to chronic disease. Renadyl™, the first and only dietary ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):